ACA
BIO icon

Atlas Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Atlas Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$41.7K – 904
2022
Q3 		$41.7K Hold
100
– – 0.01% 557
2022
Q2 		$49.5K Buy
+100
New +$52.1K 0.01% 563

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Atlas Capital Advisors's BIO Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 100 shares — an estimated $41.7K sold.

Atlas Capital Advisors first reported a position in BIO in Q2 2022 and held it in 2 quarters. The position peaked at $49.5K in Q2 2022. 470 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

  • Atlas Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 100 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $41.7K.
  • Atlas Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and held it in 2 quarters.
  • Atlas Capital Advisors's Bio-Rad Laboratories Class A position peaked at $49.5K in Q2 2022.
  • 470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.